Main Article Content
Voriconazole is a second-generation triazole antifungal drug, which exhibits characteristics of wide antibacterial spectru, high biological utilization and passing through plasma brain barrier. The most common adverse reactions of voriconazole include neurological dysfunction, visual disturbance, abnormal liver function and renal dysfunction, here, this is the report to show that voriconazole can induce allergic purpura. The present report mainly describes one patient with rare adverse reactions, namely mixed type allergic purpura induced by high concentration of plasma drug caused by slow metabolism of voriconazole. Aafter using voriconazole, the patient was diagnosed as mixed type allergic purpura, methylprednisolone sodium succinate was given for treatment. After treatment, abdominal pain and abdominal distension of the patient was significantly alleviated, and the color of rash faded. Edemas of both lower extremities were significantly improved, and the color of stool turned into yellow. The measured concentration of plasma drug of voriconazole was 15 Î¼g/ml on admission of the patient. Genetic testing result demonstrated that the patient belonged to heterozygous mutation of CYP2C19*1*2, and the metabolism of voriconazole of the patient was relatively slow. The report prompted the clinicians that there were significant metabolic differences of voriconazole in different populations. Therefore, monitoring of drug concentration should be conducted timely in the clinical application to reduce the risk of medication and achieve individualized administration.
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under aÃ‚Â Creative Commons Attribution LicenseÃ‚Â that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÃ‚Â The Effect of Open Access).